Check 35,000+ stocks against 26 valuation models and 37 quality factors

Cipher Pharmaceuticals Inc (CPHRF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Cipher Pharmaceuticals Inc $21.48, price $9.63, upside +123.1%, quality 77 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · Home Canada · ISIN CA17253X1050

Broad data Sep 24, 2026

Cipher Pharmaceuticals Inc

CPHRF · US

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value $21.48 · Strongly undervalued (+123.1%)

✓Quality 77/100

!Mixed Growth (revenue 5y +18.5 %/yr)

✓Highly profitable · 60.6% net margin (TTM)

✓Low debt · generates free cash flow

✓Wide moat 85/100

26 models, one by oneBear $12.19 to bull $37.24 Growth analysisrevenue history, year by year Quality 77/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Cipher Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.05 – $14.34 · fair‑value band $12.19 – $37.24 · the $9.63 price screens below the $21.48 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Stock analysis

Cipher Pharmaceuticals Inc (CPHRF) currently trades at $9.63, while our model-based Fair Value estimate is $21.48, implying the stock looks roughly 55.2% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $29.01 per share, and 18 of the 24 models we run sit above the $9.63 price.

Bear case: the Asset-Based group reads lowest at $3.33, and 6 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $12.19 (bear) to $37.24 (bull), the price of $9.63 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cipher Pharmaceuticals Inc reported revenue of $50.5M in FY2025 versus $21.9M in FY2021, a compound +23.1%/yr. Reported net income was $27.3M in FY2025, compounding +37.0%/yr from FY2021.

Key figures

Market cap $290M · P/E ratio 8.1 · P/S ratio 4.38 · EPS (TTM) $1.19 · Net margin 54.2% · Return on equity 25.9% · Return on assets (EBIT) 13.1% · Operating margin 44.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 123%, CPHRF screens cheaper than that median.

Fair Value models

Bear $12.19 Fair Value $21.48 Bull $37.24

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.8998 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $12.90 $19.65 $36.00 77

Growth DCF $12.29 $20.56 $33.74 76

EPV $4.37 $4.88 $5.30 74

All 24 models by family

DCF Models

FCF DCF $12.90 $19.65 $36.00 77

Owner Earnings $14.97 $28.56 $51.73 73

5Y Revenue Exit $7.47 $11.73 $18.83 71

5Y EBITDA Exit $10.73 $18.90 $32.11 73

5Y P/E Exit $15.36 $30.63 $49.89 68

10Y Revenue Exit $9.27 $14.63 $20.84 66

10Y EBITDA Exit $11.34 $19.73 $33.90 66

10Y P/E Exit $14.11 $26.97 $48.24 61

Earnings-Based

Graham-Dodd $7.32 $48.92 $68.52 63

Lynch FV $14.31 $20.44 $26.57 61

PEG = 1.0 $14.31 $20.44 $26.57 57

EPV $4.37 $4.88 $5.30 74

Multiples

P/E Multiple $17.76 $23.68 $29.60 63

P/S Multiple $5.22 $6.95 $8.69 58

P/B Multiple $13.72 $18.30 $22.87 55

EV/EBIT $8.57 $11.39 $14.21 66

EV/EBITDA $10.06 $13.38 $16.71 67

EV/Revenue $4.27 $6.06 $7.85 54

Asset-Based

NCAV (Graham) $2.49 $3.33 $4.97 54

Growth DCF

Growth DCF $12.29 $20.56 $33.74 76

Rev-Margin DCF $7.47 $11.92 $18.06 72

Economic Profit

Residual Income $5.49 $7.38 $11.94 68

ROIC Compounder $4.37 $4.88 $5.72 72

Growth Earnings

Growth-Adj P/E $20.31 $29.01 $37.71 67

Open the full fair value analysis →

Notify me when CPHRF reaches fair value

Put CPHRF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 77/100

Of which business quality 75 · Market factors (momentum, volatility) 32

Profitability 67

Margins and returns on capital today

Quality Growth 80

Are margins and returns improving?

Cashflow 85

Earnings quality: real cash, not paper profit

Fin. Strength 82

Balance sheet, leverage, solvency risk

Investment 33

Disciplined investing over empire-building

Low Volatility 71

Calm price path (market factor)

Momentum 18

Price trend over the last 3–12 months (market factor)

52W Momentum 12

Distance to the 52-week high (market factor)

Net Issuance 89

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 92/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+51.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+34.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.5%

Start year 2020 (pandemic). Over 10 years: +3.9% a year

Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.3%

’13

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+45.3%

Earnings growth per share plus dividend.

Earnings per share, growth per year+45.3%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.45.3% vs 32.0%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.56% → 33%

Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price

The price assumes less growth than the company has delivered so far and less than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

−4.7%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+18.9%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −6.9% a year for the price and +16.1% for the forecasts.

Forecast 2026 (sales)+44.7%

Forecast 2027 (sales)+15.8%

Projected 2028 (sales)+14.0%

Projected 2029 (sales)+12.3%

Projected 2030 (sales)+10.6%

Watch CPHRF, get fair value alerts →

Compare Cipher Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 10/13 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 77 · Top 25%

Fair Value upside +8.8% · Above median

Profitability

Return on equity (TTM) 25.9% · Top 25%

Return on assets 7.9% · Top 25%

Net margin (TTM) 60.6% · Top 25%

Operating margin (TTM) 44.7% · Top 25%

Growth and dividend

Revenue growth 4.0% · Below median

Balance sheet

Debt / equity 0.04× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 8.1× · Cheapest 25%

P/B 2.29× · Pricier than median

P/S (TTM) 5.69× · Priciest 25%

P/FCF 9.8× · Cheaper than median

EV/EBITDA 10.7× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cipher Pharmaceuticals Inc · Fair Value
$21.48 +55%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CPHRF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Cipher Pharmaceuticals Inc · Fair Value</span><br><b style="font-size:20px">$21.48</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+55%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Cipher Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/CPHRF

Frequently asked questions

Is Cipher Pharmaceuticals Inc (CPHRF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $21.48 versus a price of $9.63, about +123% upside (undervalued).

What is the fair value of CPHRF?

Our model-based fair value for Cipher Pharmaceuticals Inc is $21.48 (as of Sep 24, 2026), built from audited fundamentals. The current price: $9.63.

What is the quality score of CPHRF?

Cipher Pharmaceuticals Inc has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Cipher Pharmaceuticals Inc (CPHRF)?

Our model-based price target is the fair value of $21.48 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $12.19, optimistic scenario $37.24. It is a calculation from audited fundamentals, not an analyst target.

What is the Cipher Pharmaceuticals Inc stock forecast for 2026?

Our models put fair value at $21.48, about +123% upside versus a price of $9.63 (undervalued). Cautious scenario $12.19, optimistic scenario $37.24. The calculation is refreshed regularly with new filings.

What is the revenue of Cipher Pharmaceuticals Inc (CPHRF)?

Cipher Pharmaceuticals Inc reported trailing-twelve-month revenue of about $50.9M (latest available figure, as of Sep 24, 2026).

What growth is priced into Cipher Pharmaceuticals Inc (CPHRF)?

For today's price to be fair in a discounted-cash-flow model, Cipher Pharmaceuticals Inc would have to grow free cash flow by -4.7 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.5 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of CPHRF use?

Our models discount Cipher Pharmaceuticals Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.48, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cipher Pharmaceuticals Inc that is -4.7 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.

How much growth has Cipher Pharmaceuticals Inc (CPHRF) delivered so far?

Over the past 5 years revenue at Cipher Pharmaceuticals Inc grew +18.5 % a year. The price currently implies -4.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Cipher Pharmaceuticals Inc (CPHRF) growing?

The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Cipher Pharmaceuticals Inc (-4.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Cipher Pharmaceuticals Inc (CPHRF)?

The free-cash-flow yield on the price is 12.09 %: that much free cash flow Cipher Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Cipher Pharmaceuticals Inc (CPHRF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cipher Pharmaceuticals Inc it is $21.48 per share (as of Sep 24, 2026), against a price of $9.63. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Cipher Pharmaceuticals Inc stock overvalued or undervalued in 2026?

As of Sep 24, 2026, CPHRF trades below its calculated fair value: price $9.63, fair value $21.48, a gap of about +123% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CPHRF?

No. The price is what the market pays today ($9.63); the fair value is what the company's own numbers justify ($21.48). For Cipher Pharmaceuticals Inc the two are $11.85 per share apart. That gap is exactly why we show both numbers side by side.

How much is Cipher Pharmaceuticals Inc worth?

The market values Cipher Pharmaceuticals Inc at about $290M (market capitalisation, as of Sep 24, 2026). Per share that is $9.63; our models calculate a fair value of $21.48 per share.

What do the bullish and bearish scenarios say about CPHRF?

Our models span a range for Cipher Pharmaceuticals Inc: cautious scenario $12.19, base $21.48, optimistic $37.24 per share (as of Sep 24, 2026, price $9.63). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of CPHRF?

Cipher Pharmaceuticals Inc trades at a price-to-earnings ratio of 8.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $21.48 is built from several models across several years. Other multiples: P/B 2.3, P/S 5.7, EV/EBITDA 10.7.

How solid is the balance sheet of Cipher Pharmaceuticals Inc (CPHRF)?

Balance-sheet figures for Cipher Pharmaceuticals Inc (as of Sep 24, 2026): return on equity 25.9%, debt of 0.04 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.

How far is CPHRF from its 52-week high?

Cipher Pharmaceuticals Inc trades at $9.63, about 33% below its 52-week high of $14.34 and 3% above the low of $9.33 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $21.48 is for.

Which stocks are comparable to Cipher Pharmaceuticals Inc?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Cipher Pharmaceuticals Inc stock attractive at the current price?

The data as of Sep 24, 2026: price $9.63, calculated fair value $21.48 (+123%), Quality Score 77/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CPHRF calculated?

We run Cipher Pharmaceuticals Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $21.48, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Cipher Pharmaceuticals Inc currently trades 55 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Cipher Pharmaceuticals Inc (CPHRF)?

The closing price on Oct 2, 2026 was $9.63. Our model-based fair value is $21.48, about +123% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Cipher Pharmaceuticals Inc right now?

The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($12.19). The market is more pessimistic than our downside scenario. The model range is unusually wide ($12.19 to $37.24). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Cipher Pharmaceuticals Inc

How large is the market capitalisation of Cipher Pharmaceuticals Inc (CPHRF)?

The market capitalisation of Cipher Pharmaceuticals Inc is $290M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Cipher Pharmaceuticals Inc (CPHRF)?

The price-to-sales ratio of Cipher Pharmaceuticals Inc is 4.38 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Cipher Pharmaceuticals Inc (CPHRF)?

Earnings per share at Cipher Pharmaceuticals Inc are $1.19 (price ÷ EPS = P/E 8.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Cipher Pharmaceuticals Inc (CPHRF)?

The net margin of Cipher Pharmaceuticals Inc is 54.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Cipher Pharmaceuticals Inc (CPHRF)?

The return on equity (ROE) of Cipher Pharmaceuticals Inc is 25.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Cipher Pharmaceuticals Inc (CPHRF)?

On an EBIT basis the return on assets of Cipher Pharmaceuticals Inc is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Cipher Pharmaceuticals Inc (CPHRF)?

The operating margin of Cipher Pharmaceuticals Inc is 44.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Cipher Pharmaceuticals Inc (CPHRF)?

Revenue at Cipher Pharmaceuticals Inc is growing +4.0% versus a year earlier (3y avg +34.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Cipher Pharmaceuticals Inc (CPHRF)?

Earnings per share at Cipher Pharmaceuticals Inc are growing +140% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Cipher Pharmaceuticals Inc (CPHRF) carry?

The net debt of Cipher Pharmaceuticals Inc is $22.2M (fiscal year 2024, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Cipher Pharmaceuticals Inc in the live analysis

One click puts Cipher Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.